INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 158 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.65 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $403,000 | +6.1% | 7,405 | -61.3% | 0.00% | 0.0% |
| Q3 2020 | $380,000 | -5.5% | 19,132 | +0.1% | 0.00% | 0.0% |
| Q2 2020 | $402,000 | +75.5% | 19,116 | +2.2% | 0.00% | +100.0% |
| Q1 2020 | $229,000 | -16.4% | 18,704 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $274,000 | +9.6% | 18,704 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $250,000 | -18.3% | 18,704 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $306,000 | -4.1% | 18,704 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $319,000 | +41.2% | 18,704 | +136.3% | 0.00% | +100.0% |
| Q3 2018 | $226,000 | +4.6% | 7,914 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $216,000 | -2.3% | 7,914 | -31.3% | 0.00% | 0.0% |
| Q4 2017 | $221,000 | -22.7% | 11,516 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $286,000 | +55.4% | 11,516 | 0.0% | 0.00% | +100.0% |
| Q2 2017 | $184,000 | +13.6% | 11,516 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $162,000 | – | 11,516 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 752,024 | $100,884,000 | 18.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 420,859 | $56,458,000 | 4.40% |
| Discovery Value Fund | 922,411 | $123,741,000 | 3.63% |
| MPM BioImpact LLC | 162,620 | $21,815,000 | 3.38% |
| Ally Bridge Group (NY) LLC | 65,000 | $8,720,000 | 2.56% |
| ARK Investment Management | 6,743,556 | $904,648,000 | 2.17% |
| Integral Health Asset Management, LLC | 50,000 | $6,708,000 | 1.93% |
| Yorktown Management & Research Co Inc | 18,300 | $2,455,000 | 1.85% |
| Interchange Capital Partners, LLC | 8,191 | $1,098,000 | 1.84% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $14,950,000 | 1.76% |